Dr. Greenbaum is Director of the Diabetes Program at Benaroya Research Institute (BRI) in Seattle. BRI is a non-profit research center focused on translational and clinical studies of type 1 diabetes (T1D) and other immune mediated diseases.
Dr. Greenbaum is a clinical investigator who works to alter the course of T1D through understanding the causes of disease, and testing interventions to alter immune mediated beta cell dysfunction. After medical school at Brown University, she completed her endocrinology fellowship at the University of Washington. Dr. Greenbaum’s expertise includes clinical trial design and implementation as well as discovery and evaluation of biomarkers for disease course and response to therapy.
Dr. Greenbaum serves as Chair of Type 1 Diabetes TrialNet, an NIH sponsored international consortium to test disease modifying therapies in T1D. Dr. Greenbaum serves on various national and international scientific review committees and has had the privilege of working with many outstanding Australian investigators aiming to understand and cure T1D including John Wentworth and Peter Colman, Australian TrialNet PIs. She is on BRI’s Institutional Review Board and Board of Directors.
Abstracts this author is presenting: